First case of Eastern Equine Encephalitis reported in horse in Hamilton since 2019
This rare, but serious, viral disease can cause inflammation of the brain in severe cases, starting with a sudden headache, high fever, chills, and vomiting.
Symptoms, which usually appear in humans three to 10 days after being bitten by an infected mosquito, normally include a mild flu-like illness with fever, headache, and fatigue.
Most people who are bitten by an infected mosquito, however, don't develop any symptoms.
Eastern Equine Encephalitis is typically found in a virus carried by wild birds, however humans and horses bitten by an infected mosquito can become ill with EEE, the municipality said in a news release.
The City of Hamilton noted that there are no reports of human illness caused by this virus in Hamilton at this time.
Dr. Bart Harvey, the city's associate medical officer of health, said while the risk of being infected with EEE is low, this confirmed case serves as a reminder to residents to take precautions to avoid illness spread by mosquitos.
'Employing simple preventive measures such as using insect repellent containing DEET or Icaridin, covering up, and removing standing water on your property to prevent mosquito breeding will reduce your risk while you enjoy the outdoors. The risk of these infections will drop once there is a heavy frost that reduces the number of mosquitoes.'
Hamilton Public Health Services is providing the following tips to avoid being bitten by mosquitos:
Use a mosquito repellent (bug spray) containing DEET or Icaridin.
Avoid areas where mosquitoes are known to be present or cover up by wearing light coloured clothing with long sleeves and long pants when in wooded areas, on the golf course, or in the garden, especially at dawn and dusk when mosquitoes are most active.
Reduce mosquito breeding sites by removing standing water at least weekly from your property. Mosquitoes lay their eggs in very shallow standing water. If you remove the standing water, they cannot lay eggs.
Horses can and should be vaccinated against EEE and West Nile Virus.
'(We) continually assesses the risk for human illness as part of a comprehensive vector-borne disease surveillance and prevention program. The City is currently completing its third round of mosquito larvicide treatments on city street catch basins, in addition to treatment of surface waters on public land,' a release read.
More information about Hamilton's mosquito control program can be found online.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
42 minutes ago
- CBC
B.C. First Nations launch drug trial to combat mange in declining bighorn sheep population
Social Sharing Residents of the South Okanagan in B.C. have noticed an increase in psoroptic mange, a parasitic skin disease, among the area's bighorn sheep. A decline in their population is prompting a new study. Research for the study, led by the Okanagan Nation Alliance (ONA), a First Nations tribal council, began in February and will continue until July 2026. The alliance says big horn sheep are woven into the history of the Syilx people, with their presence reflecting the health of the land and the balance between people and nature. The Syilx are indigenous to the Okanagan, and their territory reaches into the United States. The Wild Sheep Society of British Columbia is helping fund the research, which also involves a number of provincial and regional biologists. It says B.C. is home to some of the largest and most diverse populations of wild sheep in North America. Mackenzie Clarke, ONA Wildlife Program lead, says that all bighorns from Penticton down to the United States have the skin disease. "There's a little mite that eats away at that top surface layer. it causes weeping sores, scabs and build-up of really itchy skin, so the sheep can't stop itching … they have a lot of hair loss," she told CBC's Daybreak South. Hair loss and hearing loss, because mites build up crust inside of sheep's ears, can have fatal outcomes, she says. Some sheep die due to exposure during the winter when they lose their hair, and hearing loss makes the sheep vulnerable to predators and vehicles on the road. Clarke says that researchers believe psoroptic mange here originated from a domestic rabbit farm in B.C. During a previous trial, genetic testing was done on the sheep, and researchers say they are certain the disease came from a domestic rabbit farm that was in close proximity to the sheep. She says that no wild rabbits in the area have the disease and that the domestic rabbit farm doesn't exist anymore. "It can switch between hosts, so that's why we're wanting to kick off this drug trial now, if we can, to try to get a treatment for it, before it does potentially host switch again," she said. Mange medication trial Bighorn sheep were captured, and two different drugs are being tested to see which is more effective in mitigating mange and which lasts longer. Fluralaner and moxidectin are the drugs, sourced from Australia. The Penticton Indian Band, a partner in the project, is holding the sheep. A previous mange mitigation trial from 2016 that also happened within the Penticton Indian Band was an inspiration for this study, says Clarke. She says that fluralaner was used in the previous mange trial and worked, and that moxidectin is used in the UK on domestic sheep. She says if the drugs work, all bighorn sheep in the South Okanagan will get it. Decline in bighorn sheep Psoroptic mange is limited to the South Okanagan area west of Penticton and was first detected there in 2011. Clarke says that since then, 60 per cent of bighorn sheep populations have declined. She hopes the study helps rejuvenate those numbers. Lia McKinnon shares those sentiments. McKinnon is a stewardship biologist with Okanagan Similkameen Stewardship Society, an organization that focuses on wildlife restoration and has lived in the Okanagan for over 30 years. She told CBC News that the study "is amazing, there are so many threats to the bighorn sheep." Another threat to the sheep is pneumonia, which Clarke says the bighorn sheep in the South Okanagan also have. McKinnon remembers 90 per cent of the bighorn population "dying off" during the 90s because of a spike in pneumonia — the study hopes to address that issue as well, she says. "One really cool thing about the work being done is that it is being done by the Penticton Indian band in conjunction with the Okanagan Nation Alliance, and the province is involved.
CBC
42 minutes ago
- CBC
Tick-borne Rocky Mountain spotted fever spreading in Canada
Quebec has reported its first case of the potentially deadly tick-borne disease Rocky Mountain spotted fever. The disease has also been reported in dogs in Ontario. Here's what you need to know about preventing, identifying and treating the disease. What is Rocky Mountain spotted fever? Rocky Mountain spotted fever is a disease caused by the bacteria Rickettsia ricketssiae. Symptoms in humans can include fever, headache, nausea or vomiting, stomach pain, muscle pain and lack of appetite. The disease is named for the red rash that develops two to four days after the fever begins. The rash can range from pinpoint dots to red splotches. The disease can be treated with the common antibiotic doxycyclone, and most people make a full recovery. But it can be deadly in five to 10 per cent of cases in the U.S. even with treatment, reports the U.S.-based Cleveland Clinic. Without treatment, one in four people die of the disease. Researchers try to curb tick populations as diseases spread 19 days ago Scientists say ticks are showing up in places they weren't before, so Canadian researchers are turning to new methods to curb tick populations and their impact. Dogs can also get Rocky Mountain spotted fever. Dr. Scott Weese, director of the Centre for Public Health and Zoonese at the University of Guelph, said symptoms in dogs include fever, malaise, enlarged lymph nodes, loss of appetite and muscle aches that make the animals reluctant to move. The rash can sometimes be seen inside the dog's mouth. As with humans, the disease can be deadly in dogs, and Weese said one of the first dogs identified with the disease in Ontario died of it. How is it transmitted? It can't be transmitted from person to person. It's only acquired from tick bites — typically the American dog tick (Demacentor variabilis), which is found from eastern Alberta to Nova Scotia, especially in the southern parts of those provinces. Weese says despite its name, it doesn't target dogs specifically, but a variety of large mammals, including humans. Previously, people didn't worry about American dog ticks because they didn't carry Lyme disease, which people get from the blacklegged or deer tick. "Now we're having to change our tune a little bit, realizing that this tick might not be as benign as we thought around here," Weese said. Like black-legged ticks, American dog ticks are found in grassy and wooded areas. Ticks can also hitch-hike between dogs or from dogs to humans — something Weese thinks happened to him the other day with his own dog at home. Other ticks that can carry Rocky Mountain spotted fever include the Rocky Mountain wood tick (Dermacentor andersoni) and the brown dog tick (Rhicephalus sanguineus). Where is the disease found? The U.S. sees 6,000 cases per year, especially in North Carolina, Tennessee, Missouri, Arkansas and Oklahoma, the Cleveland Clinic reports. In Canada, the disease was known but rare in B.C., with an incidence of one case per 500,000 people in 2019. WATCH | Tick-borne illnesses are on the rise. Here's what to look out for: Tick-borne illnesses are on the rise. Here's what to look out for 1 month ago Dr. Samir Gupta, a Toronto-based respirologist, is warning of an increase in tick bites and tick-borne illnesses across Canada. Ticks are parasites that feed on the blood of wild animals and are known to transmit bacteria through bites. There have been occasional cases of Rocky Mountain spotted fever reported in other parts of the country. A 73-year-old woman was diagnosed with the disease in 2023 after travelling from Saskatchewan to Ontario, and being in contact with her son's two dogs in Ottawa. The Ottawa doctors who saw the case said the disease's expansion north into areas where it hadn't been seen before was likely linked to milder winters and hotter, drier summers linked to climate change, which allow ticks to expand their range. Earlier this year, a cluster of cases in dogs was linked to Long Point Provincial Park on Lake Erie in Ontario. Weese said such a large group in a small area was a surprise. "That would suggest that this is quite well-established, at least in some areas." This week, Dr. Alex Carignan, a microbiologist and infectious disease specialist with the regional health authority in Estrie, Que., reported a "recent" case in the province's Eastern Townships. Weese noted the Quebec case also seems to have been locally acquired, raising questions about how far the disease has spread in Canada. Dr. Isaac Bogoch, an infectious disease specialist based at Toronto General Hospital, said the Ontario dog infections and the detection of Rickettsia bacteria in ticks north of the border had shown that the disease was already in Canada. "The real question is how much of it is here and what's the geographic distribution." He added that other tick-borne diseases such as Lyme disease, anaplasmosis and babesiosis have spread more widely over recent years as shorter, warmer winters allow tick populations to push north. What should people do to protect themselves and their pets? Both Bogoch and Weese recommend people take precautions to avoid being bitten by ticks. This can include staying on trails and away from places such as long grass and leaf litter; wearing long sleeves, long pants and insect repellent when possible while in areas where ticks might be; checking for ticks on themselves and their dogs after visiting such areas; and removing ticks promptly if found. Weese said people with dogs are at higher risk because they're more likely to walk in areas with higher risk of tick exposure and because dogs can sometimes bring ticks into homes in their fur. Giving dogs oral or topical tick preventive medications can greatly reduce the risk of exposure, Weese said. However, it doesn't replace other measures, and may not be as effective with Rocky Mountain spotted fever as it is with Lyme disease, since the former is transmitted more quickly. Bogoch said health-care workers should be aware there are tick-transmitted diseases beyond Lyme that they should look out for, so that suspected cases of Rocky Mountain spotted fever can be treated immediately. Weese recommended that if people or their pets fall ill after visiting wooded or grassy areas that might have ticks or Rocky Mountain spotted fever, they should mention the possible exposure to their doctor or vet to ensure prompt diagnosis and treatment. He also noted that while people should be aware of these diseases, they're still rare in Canada.
Globe and Mail
an hour ago
- Globe and Mail
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025 Time: 1:00 PM - 1:30 pm, Eastern Time Location: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer info@ (415) 506-8462 Investor Relations Contact: Jami Taylor Investor Relations Advisor investors@ (415) 506-8462 Media Contact: Mark Corbae ICR Healthcare (203) 682-8288
